LINEAGE CELL THERAPEUTICS IN's ticker is LCTX and the CUSIP is 53566P109. A total of 77 filers reported holding LINEAGE CELL THERAPEUTICS IN in Q3 2020. The put-call ratio across all filers is - and the average weighting 0.1%.
Quarter-by-quarter ownership
Value | Shares | Weighting | ||||
---|---|---|---|---|---|---|
Q2 2023 | $115,361 | +203.9% | 81,816 | +223.3% | 0.00% | – |
Q1 2023 | $37,959 | +5.8% | 25,306 | -17.5% | 0.00% | – |
Q4 2022 | $35,875 | -97.3% | 30,662 | -94.3% | 0.00% | -100.0% |
Q4 2021 | $1,325,000 | -9.5% | 540,824 | -6.9% | 0.00% | 0.0% |
Q3 2021 | $1,464,000 | -60.9% | 580,788 | -55.8% | 0.00% | -62.5% |
Q2 2021 | $3,747,000 | +27.1% | 1,314,567 | +4.8% | 0.01% | 0.0% |
Q1 2021 | $2,948,000 | +206.1% | 1,254,531 | +129.3% | 0.01% | +166.7% |
Q4 2020 | $963,000 | +388.8% | 547,215 | +160.6% | 0.00% | +200.0% |
Q3 2020 | $197,000 | -31.1% | 210,005 | -36.2% | 0.00% | 0.0% |
Q2 2020 | $286,000 | +111.9% | 328,941 | +102.3% | 0.00% | 0.0% |
Q1 2020 | $135,000 | -57.1% | 162,633 | -54.0% | 0.00% | 0.0% |
Q4 2019 | $315,000 | -3.4% | 353,705 | +6.2% | 0.00% | 0.0% |
Q3 2019 | $326,000 | – | 333,095 | – | 0.00% | – |
Download |
Other shareholders
Name | Shares | Value | Weighting ↓ |
---|---|---|---|
BROADWOOD CAPITAL INC | 34,935,485 | $39,477,000 | 3.01% |
Raffles Associates | 2,080,536 | $2,351,000 | 2.51% |
Defender Capital, LLC. | 5,184,035 | $5,862,000 | 2.30% |
Prescott General Partners LLC | 1,851,851 | $2,093,000 | 0.16% |
DAFNA Capital Management LLC | 140,000 | $158,000 | 0.04% |
Fort Sheridan Advisors LLC | 83,931 | $95,000 | 0.03% |
Long Focus Capital Management, LLC | 215,000 | $243,000 | 0.02% |
XTX Topco Ltd | 72,807 | $82,000 | 0.02% |
Ergoteles LLC | 490,895 | $555,000 | 0.02% |
Beirne Wealth Consulting Services, LLC | 45,000 | $51,000 | 0.02% |